Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I Populations
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
Pinnacle Identifies Gold-Silver Mineralization at Historic La Dura Mine, Extending Mineralized Horizon to Almost 500 Metres
Silver Dollar Discovers New Mineralized Zone at the Nora Silver-Gold Project and Receives Drill Permit
Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States
